ICON Public Limited (NASDAQ:ICLR) – Stock analysts at Truist Securiti dropped their Q3 2021 earnings per share estimates for shares of ICON Public in a research report issued to clients and investors on Monday, May 10th. Truist Securiti analyst S. Draper now anticipates that the medical research company will earn $2.15 per share for the quarter, down from their prior estimate of $2.17. Truist Securiti also issued estimates for ICON Public’s Q4 2021 earnings at $2.21 EPS.
ICLR has been the topic of several other research reports. Credit Suisse Group lifted their price target on ICON Public from $240.00 to $245.00 and gave the company an “outperform” rating in a research note on Wednesday, May 5th. Deutsche Bank Aktiengesellschaft increased their target price on shares of ICON Public from $179.00 to $208.00 and gave the stock a “hold” rating in a report on Wednesday, March 3rd. Bank of America initiated coverage on shares of ICON Public in a report on Tuesday, April 13th. They set a “neutral” rating on the stock. UBS Group upgraded shares of ICON Public from a “neutral” rating to a “buy” rating and raised their target price for the company from $207.00 to $232.00 in a research report on Monday, March 8th. Finally, Mizuho upped their price target on shares of ICON Public from $217.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, May 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $232.60.
ICON Public (NASDAQ:ICLR) last released its earnings results on Tuesday, April 27th. The medical research company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.97 by $0.09. ICON Public had a net margin of 11.95% and a return on equity of 21.42%. The firm had revenue of $858.20 million for the quarter, compared to analyst estimates of $780.49 million.
A number of hedge funds and other institutional investors have recently bought and sold shares of ICLR. Allred Capital Management LLC acquired a new position in ICON Public during the 1st quarter worth about $33,000. Sowell Financial Services LLC lifted its stake in shares of ICON Public by 74.7% in the fourth quarter. Sowell Financial Services LLC now owns 255 shares of the medical research company’s stock worth $50,000 after acquiring an additional 109 shares during the period. Atlas Private Wealth Management boosted its holdings in ICON Public by 250.0% in the first quarter. Atlas Private Wealth Management now owns 350 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 250 shares during the last quarter. Cullen Frost Bankers Inc. increased its position in ICON Public by 66.5% during the 1st quarter. Cullen Frost Bankers Inc. now owns 814 shares of the medical research company’s stock valued at $160,000 after purchasing an additional 325 shares during the period. Finally, Tributary Capital Management LLC bought a new position in ICON Public during the 1st quarter worth approximately $201,000. Institutional investors and hedge funds own 81.70% of the company’s stock.
About ICON Public
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Story: Gross Domestic Product (GDP)
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.